April 18, 2016 — A lawsuit has been filed against Sanofi-Aventis by a woman from Ohio who used the chemotherapy drug Taxotere and experienced permanent hair loss (alopecia).
The lawsuit (PDF) was filed on January 22 in the U.S. District Court for the Northern District of Ohio by plaintiff Hattie Carson (Case No. 1:16-cv-00165).
After Carson was diagnosed with breast cancer in April 2004, she underwent surgery and chemotherapy treatments that included Taxotere. After completing treatment, she was diagnosed with permanent alopecia. According to the lawsuit:
“Defendants [preyed] on one of the most vulnerable groups of individuals at the most difficult time in their lives. … Although alopecia is a common side effect related to chemotherapy drugs, permanent alopecia is not.”
Lawyers say Sanofi-Aventis knew about the risk of permanent hair loss from Taxotere long before providing warnings in the United States. In the 1990s, the drug-maker sponsored a study called GEICAM 9805 in which alopecia occurred in 9.2% of women treated with Taxotere in conjunction with other chemotherapy drugs.
Permanent alopecia was added to labels in Europe in 2005 and Canada in 2012. It is not clear why it took until December 2015 for label updates to appear in the United States. Before the changes, the label reassured women that “hair generally grows back” after treatment ends.
Do I have a Taxotere Lawsuit?
The Schmidt Firm, PLLC is currently accepting Taxotere induced injury cases in all 50 states. If you or somebody you know has been diagnosed with permanent baldness, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.